Julio C Chavez, Adel S Girgis, Marian N Aziz, Shilpi Khurana, Brandon Carr, Guido F Verbeck, Siva S Panda
{"title":"布洛芬与3,5-二芳基吡啶-4-哌啶酮的杂化偶联物:消炎药发现的新途径。","authors":"Julio C Chavez, Adel S Girgis, Marian N Aziz, Shilpi Khurana, Brandon Carr, Guido F Verbeck, Siva S Panda","doi":"10.1002/cmdc.202500342","DOIUrl":null,"url":null,"abstract":"<p><p>Nonsteroidal anti-inflammatory drugs (NSAIDs) have been crucial in managing inflammation, pain, and fever since their introduction in 1897. Despite their widespread use, NSAIDs often face limitations due to gastrointestinal side effects from the nonselective inhibition of cyclooxygenase (COX) isoenzymes, COX-1 and COX-2. While selective COX-2 inhibitors reduce gastrointestinal toxicity, they come with increased cardiovascular risks. This study investigates the synthesis and biological evaluation of novel hybrid NSAID conjugates incorporating 3,5-diarylidene-4-piperidinone, ibuprofen, and amino acids. These hybrid molecules are designed to enhance anti-inflammatory efficacy while minimizing adverse effects. The synthesized compounds are evaluated for COX inhibition and their effects on inflammatory mediators such as interleukin-6, tumor necrosis factor-alpha, and nitric oxide. Computational studies, including molecular docking and ADME (absorption, distribution, metabolism, and excretion) analyses, are performed to clarify the mechanisms of action and to predict pharmacokinetic properties. The findings indicate that some hybrid conjugates display promising anti-inflammatory properties, necessitating further investigation for their potential therapeutic applications.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":" ","pages":"e202500342"},"PeriodicalIF":3.4000,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Hybrid Conjugates of Ibuprofen and 3,5-Diarylidene-4-Piperidone: A New Avenue in Anti-Inflammatory Drug Discovery.\",\"authors\":\"Julio C Chavez, Adel S Girgis, Marian N Aziz, Shilpi Khurana, Brandon Carr, Guido F Verbeck, Siva S Panda\",\"doi\":\"10.1002/cmdc.202500342\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Nonsteroidal anti-inflammatory drugs (NSAIDs) have been crucial in managing inflammation, pain, and fever since their introduction in 1897. Despite their widespread use, NSAIDs often face limitations due to gastrointestinal side effects from the nonselective inhibition of cyclooxygenase (COX) isoenzymes, COX-1 and COX-2. While selective COX-2 inhibitors reduce gastrointestinal toxicity, they come with increased cardiovascular risks. This study investigates the synthesis and biological evaluation of novel hybrid NSAID conjugates incorporating 3,5-diarylidene-4-piperidinone, ibuprofen, and amino acids. These hybrid molecules are designed to enhance anti-inflammatory efficacy while minimizing adverse effects. The synthesized compounds are evaluated for COX inhibition and their effects on inflammatory mediators such as interleukin-6, tumor necrosis factor-alpha, and nitric oxide. Computational studies, including molecular docking and ADME (absorption, distribution, metabolism, and excretion) analyses, are performed to clarify the mechanisms of action and to predict pharmacokinetic properties. The findings indicate that some hybrid conjugates display promising anti-inflammatory properties, necessitating further investigation for their potential therapeutic applications.</p>\",\"PeriodicalId\":147,\"journal\":{\"name\":\"ChemMedChem\",\"volume\":\" \",\"pages\":\"e202500342\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-09-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ChemMedChem\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/cmdc.202500342\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemMedChem","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/cmdc.202500342","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Hybrid Conjugates of Ibuprofen and 3,5-Diarylidene-4-Piperidone: A New Avenue in Anti-Inflammatory Drug Discovery.
Nonsteroidal anti-inflammatory drugs (NSAIDs) have been crucial in managing inflammation, pain, and fever since their introduction in 1897. Despite their widespread use, NSAIDs often face limitations due to gastrointestinal side effects from the nonselective inhibition of cyclooxygenase (COX) isoenzymes, COX-1 and COX-2. While selective COX-2 inhibitors reduce gastrointestinal toxicity, they come with increased cardiovascular risks. This study investigates the synthesis and biological evaluation of novel hybrid NSAID conjugates incorporating 3,5-diarylidene-4-piperidinone, ibuprofen, and amino acids. These hybrid molecules are designed to enhance anti-inflammatory efficacy while minimizing adverse effects. The synthesized compounds are evaluated for COX inhibition and their effects on inflammatory mediators such as interleukin-6, tumor necrosis factor-alpha, and nitric oxide. Computational studies, including molecular docking and ADME (absorption, distribution, metabolism, and excretion) analyses, are performed to clarify the mechanisms of action and to predict pharmacokinetic properties. The findings indicate that some hybrid conjugates display promising anti-inflammatory properties, necessitating further investigation for their potential therapeutic applications.
期刊介绍:
Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies.
ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs.
Contents
ChemMedChem publishes an attractive mixture of:
Full Papers and Communications
Reviews and Minireviews
Patent Reviews
Highlights and Concepts
Book and Multimedia Reviews.